LFB Executive Committee
Claire Biot joins LFB following a career of more than twenty years at the intersection of health policy, hospital transformation and technological innovation. An engineer, graduate of École polytechnique and the Corps des Mines, and holder of a PhD in immunology from the Institut Pasteur, she has held senior leadership positions within the French public sector, AP-HP (Greater Paris University Hospitals) and Dassault Systèmes. She returns to LFB, where she completed a one-year internship as part of her Corps des Mines training. In 2012, Claire Biot was appointed Head of Division, Health Products, at the French Social Security Directorate (Direction de la Sécurité sociale – DSS). In this role, she defined and implemented the health product coverage policy, representing the DSS on the Economic Committee for Health Products (CEPS) and on the Board of Directors of the French National Agency for Medicines and Health Products Safety (ANSM). In 2015, she was appointed Managing Director of AP-HP’s Central Agency for Health Products and Equipment (AGEPS), where she led an organisation of 500 employees across two industrial sites, with responsibility for procurement policy, logistics operations and AP-HP’s drug manufacturing facilities. She led several structuring projects, including the resolution of an ANSM injunction and a major industrial transformation. In 2019, Claire Biot joined Dassault Systèmes, a global leader in virtual twin technology, as Vice President, Life Sciences and Healthcare Industry. In this role, she defined and steered the global strategy and market development of the group’s healthcare activities and played a key role in the acquisition and integration of Medidata, Dassault Systèmes’ largest acquisition to date. Since early 2026, she has served as Vice President, Life Sciences Strategic Accounts Europe.
A former independent Director of a listed medtech company, she is a member of the Supervisory Board of Leukemia Institute Paris Saint Louis. A Knight of the French National Order of Merit, a French-American Foundation Young Leader, and an honorary doctorate recipient from Long Island University, Claire Biot has contributed to several public-interest initiatives, including an assignment entrusted to her by Prime Minister Élisabeth Borne on the funding and regulation of health products.
A former independent Director of a listed medtech company, she is a member of the Supervisory Board of Leukemia Institute Paris Saint Louis. A Knight of the French National Order of Merit, a French-American Foundation Young Leader, and an honorary doctorate recipient from Long Island University, Claire Biot has contributed to several public-interest initiatives, including an assignment entrusted to her by Prime Minister Élisabeth Borne on the funding and regulation of health products.
Bruno de Miribel joined the LFB on September 2021, as Executive Vice President Finance. Bruno de Miribel is a graduate of Centrale Paris. He started his career in strategy consulting at AT Kearney. He then spent 20 years in the Danone group, starting at LU where, after a varied career in Purchasing and Finance, he was appointed CFO in 2008. In 2010, he moved internationally as CFO Mexico and then Latin America for Danone’s Waters division. In 2014, he returned to France to develop and implement a demanding program to transform Danone’s Finance function globally. He then took on the role of CFO Europe for the Medical Nutrition business (Nutricia), a world close to the pharmaceutical industry, and in his last role he led the integration program of Danone’s Medical Nutrition and Baby Nutrition businesses, participating in the growth and development of these entities within the Group.
Fabrice Dubois joined LFB in April 2023 as Executive Vice President, Legal Affairs and Group Head of Compliance; Secretary to the Board of Directors; and a member of the Executive Committee.
He began his career at Rhône-Poulenc Rorer before joining Servier, where his responsibilities included overseeing the Insurance and Litigation departments before establishing the International Legal Coordination unit.
In 2016, Fabrice joined the biotechnology company Intercept Pharmaceuticals as Head of Legal Affairs for Europe. He supported the company’s expansion across the continent, notably by establishing subsidiaries, implementing early-access programmes and supporting commercial development.
He later joined Biogen as Head of Legal for France, Belgium and the Netherlands, where he subsequently played a key role in creating and structuring Biogen Digital Health, a division dedicated to personalised and digital medicine in neuroscience. He became the division’s Global General Counsel, leading teams based in Paris, Zurich and Boston.
He began his career at Rhône-Poulenc Rorer before joining Servier, where his responsibilities included overseeing the Insurance and Litigation departments before establishing the International Legal Coordination unit.
In 2016, Fabrice joined the biotechnology company Intercept Pharmaceuticals as Head of Legal Affairs for Europe. He supported the company’s expansion across the continent, notably by establishing subsidiaries, implementing early-access programmes and supporting commercial development.
He later joined Biogen as Head of Legal for France, Belgium and the Netherlands, where he subsequently played a key role in creating and structuring Biogen Digital Health, a division dedicated to personalised and digital medicine in neuroscience. He became the division’s Global General Counsel, leading teams based in Paris, Zurich and Boston.
Hanna Lepers joined LFB in July 2019 as Executive Vice President France Operations.
Hanna has extentive operational and strategic experience in the pharmaceutical industry aquired throughout her career in France, abroad and in global roles. She started her career in Sanofi in 1991 evolving in various roles in Business Development & Licensing, Marketing, Sales and Global Product Development. For Gilead she led successfully the French HIV business and was promoted General Manager in Switzerland. She has a proven track record, strong expertise for developing and launching speciality products. She has supported many transformation projects and managed teams for success. Hanna is working as mentor and expert for EIT Health (European Institute of Innovation & Technology).
Hanna has extentive operational and strategic experience in the pharmaceutical industry aquired throughout her career in France, abroad and in global roles. She started her career in Sanofi in 1991 evolving in various roles in Business Development & Licensing, Marketing, Sales and Global Product Development. For Gilead she led successfully the French HIV business and was promoted General Manager in Switzerland. She has a proven track record, strong expertise for developing and launching speciality products. She has supported many transformation projects and managed teams for success. Hanna is working as mentor and expert for EIT Health (European Institute of Innovation & Technology).
Vincent Loret joined the LFB in November 2022, as Executive Vice President, Industrial & Quality Operations, member of the Executive Committee. He is in charge of the operations performed on 4 sites located in France as well as all the related global functions, aiming to deliver plasma-derived medicinal products and recombinant proteins for patients.
Vincent was previously leading the Industrial Strategy & Performance function for the vaccines division at Sanofi since 2019.
Vincent started his career in vaccines manufacturing, working for Sanofi & GSK in production, Vaccines development, Plant construction, Quality Operations as well as site head, in France and abroad (Argentina, Hungary, Belgium, Singapour).
Vincent is an engineer graduated from the Toulouse National Institute of Applied Sciences (INSA)
Vincent was previously leading the Industrial Strategy & Performance function for the vaccines division at Sanofi since 2019.
Vincent started his career in vaccines manufacturing, working for Sanofi & GSK in production, Vaccines development, Plant construction, Quality Operations as well as site head, in France and abroad (Argentina, Hungary, Belgium, Singapour).
Vincent is an engineer graduated from the Toulouse National Institute of Applied Sciences (INSA)
Jose Antonio Moreno Toscano is the LFB USA & rEVO Biologics Chief Executive Officer.
Jose began his career in Corporate Development and Investor Relations, where he led M&A activities at Chr. Hansen Holding, a world leader in biosciences focused on developing and commercializing ingredients for the food, agricultural and pharmaceutical industries.
Jose served as Chief Financial Officer for Applus A/S in Copenhagen.
He led the US & Canadian subsidiaries of ALK, a publicly held Danish company that is the world leader in allergy and immunotherapy care. He held full profit & loss and operational responsibility for ALK’s Americas region, successfully growing the top and bottom line.
Then, Jose served as President and Member of the Board of Directors of Safe Harbor Compliance and Clinical Services. Jose is Industry Advisor for Fidelio Capital.
Jose brings a global perspective to our business and a significant global leadership experience, having lived and worked in several European countries as well as the US.
Jose earned his Master’s Degree in Law from the Universidad de Murcia in Spain and his MBA in International Finance and Strategy from the ENPC School of International Management in Paris.
Jose began his career in Corporate Development and Investor Relations, where he led M&A activities at Chr. Hansen Holding, a world leader in biosciences focused on developing and commercializing ingredients for the food, agricultural and pharmaceutical industries.
Jose served as Chief Financial Officer for Applus A/S in Copenhagen.
He led the US & Canadian subsidiaries of ALK, a publicly held Danish company that is the world leader in allergy and immunotherapy care. He held full profit & loss and operational responsibility for ALK’s Americas region, successfully growing the top and bottom line.
Then, Jose served as President and Member of the Board of Directors of Safe Harbor Compliance and Clinical Services. Jose is Industry Advisor for Fidelio Capital.
Jose brings a global perspective to our business and a significant global leadership experience, having lived and worked in several European countries as well as the US.
Jose earned his Master’s Degree in Law from the Universidad de Murcia in Spain and his MBA in International Finance and Strategy from the ENPC School of International Management in Paris.
Philippe Noquéro joined the LFB on April 2023 as Executive VP Operational Excellence. The creation of this new department is an initiative spearheaded by Jacques Brom, CEO of LFB since September 2022, with the goal of strengthening the teams and resources allocated to improving procedures and processes.
With a doctorate in Pharmaceutical Sciences, and as a Black Belt Master Lean & Six Sigma, Philippe Noquéro has more than 25 years of experience in the pharmaceutical sector, whether in manufacturing, continuous improvement, industrial transfer or the supply chain. During his career, he has served in positions including that of Director of Operational Excellence at Pfizer, J&J and FAMAR (CMO). Since 2013, Philippe Noquéro was European Director of Operational Excellence at Takeda.
With a doctorate in Pharmaceutical Sciences, and as a Black Belt Master Lean & Six Sigma, Philippe Noquéro has more than 25 years of experience in the pharmaceutical sector, whether in manufacturing, continuous improvement, industrial transfer or the supply chain. During his career, he has served in positions including that of Director of Operational Excellence at Pfizer, J&J and FAMAR (CMO). Since 2013, Philippe Noquéro was European Director of Operational Excellence at Takeda.
Before joining LFB, Karen Pinachyan was the Head of Global Medical Affairs for the Hematology Therapeutic Area at CSL Behring. Prior to this, Karen served as the Head of Medical Affairs for the European region at CSL Behring, where he oversaw medical strategies across key therapeutic areas, including immunology, cardiology, and transplantation.
Karen Pinachyan completed his specialization in otorhinolaryngology and head and neck surgery at the University Hospital of Marseille in France, where he also developed expertise in toxicology and pharmacovigilance. He holds a specialized Master’s degree in Healthcare Management and a diploma in Public Health.
He then transitioned to the biotechnology sector, successfully leading orphan drug designation applications with both the EMA and the FDA for cutting-edge molecules within a Marseille-based startup. Before joining CSL Behring in 2019, he also held roles in medical affairs and clinical development at Boehringer Ingelheim, Octapharma, and Roche, demonstrating a rich and varied experience across several European settings.
Karen Pinachyan completed his specialization in otorhinolaryngology and head and neck surgery at the University Hospital of Marseille in France, where he also developed expertise in toxicology and pharmacovigilance. He holds a specialized Master’s degree in Healthcare Management and a diploma in Public Health.
He then transitioned to the biotechnology sector, successfully leading orphan drug designation applications with both the EMA and the FDA for cutting-edge molecules within a Marseille-based startup. Before joining CSL Behring in 2019, he also held roles in medical affairs and clinical development at Boehringer Ingelheim, Octapharma, and Roche, demonstrating a rich and varied experience across several European settings.
Anne-Laurence is a Pharmacist with a MBA from IAE business school of Paris. She has more than 25 years of experience in the pharmaceutical industry.
Anne-Laurence started her career within IMS in 1992 and joined Servier as Product Manager in 1996. She moved to LEO Pharma France in 2001 as brand manager. Within LEO Pharma, she has held progressively senior positions in marketing, sales force management and as country manager. She was nominated general manager of Spain and Portugal in 2015, and Vice President of the Cluster France-Canada-BeneLux in 2016.
Anne-Laurence has a considerable base of knowledge in various therapeutic fields, and especially in hospital settings, and has acquired strong leadership skills and change control expertise in the course of her professional duties.
Anne-Laurence started her career within IMS in 1992 and joined Servier as Product Manager in 1996. She moved to LEO Pharma France in 2001 as brand manager. Within LEO Pharma, she has held progressively senior positions in marketing, sales force management and as country manager. She was nominated general manager of Spain and Portugal in 2015, and Vice President of the Cluster France-Canada-BeneLux in 2016.
Anne-Laurence has a considerable base of knowledge in various therapeutic fields, and especially in hospital settings, and has acquired strong leadership skills and change control expertise in the course of her professional duties.
Virginie Scanu joined LFB in March 2018 as Executive Vice President Human Resources. Virginie has extensive operational and strategic experience in Human Resources, acquired throughout her career in France and internationally. She began her career in the retail and services field before joining the pharmaceutical industry 15 years ago, notably in Novartis, GSK and ALK, as HR Director France and then Europe. In this sector, Virginie has supported many development and transformation strategic projects whether they are organizational, cultural or industrial. Virginie Scanu graduated from a Business School (KEDGE) and is a certified coach.
Didier Véron joined LFB in February 2019 as Executive VP Corporate Affairs and member of the Executive Committee. He is in charge of public affairs, market access, external communication and CSR.
Didier is also Chairman and Chief Executive Officer of the G5 Santé, a think tank of the leaders of the main French healthcare companies (bioMérieux, Guerbet, Ipsen, Laboratoires Théa, LFB, Pierre Fabre, Sanofi, Servier).
Didier was Senior Vice President, Group Public Affairs and Communications, at Ipsen from 2013 to January 2019.
After starting his career at the Fédération Nationale des Travaux Publics, Didier spent more than 20 years in the healthcare sector: first joining the General Management of the French Medicines Agency (ANSM), then joining Ipsen’s General Management in 1998. From 2005 to 2018, Didier Véron was a Director and member of the Board of Leem, the professional association of French pharmaceutical companies. Didier was Chairman of the French/European Public Affairs Commission.
Didier is a graduate of Sciences Po Paris and holds a postgraduate degree in Health Law from the University of Paris Sud. Didier is a lecturer at Sciences Po Paris. Didier has been decorated “Chevalier de l’ordre national du Mérite » (National Order of Merit).
Didier is also Chairman and Chief Executive Officer of the G5 Santé, a think tank of the leaders of the main French healthcare companies (bioMérieux, Guerbet, Ipsen, Laboratoires Théa, LFB, Pierre Fabre, Sanofi, Servier).
Didier was Senior Vice President, Group Public Affairs and Communications, at Ipsen from 2013 to January 2019.
After starting his career at the Fédération Nationale des Travaux Publics, Didier spent more than 20 years in the healthcare sector: first joining the General Management of the French Medicines Agency (ANSM), then joining Ipsen’s General Management in 1998. From 2005 to 2018, Didier Véron was a Director and member of the Board of Leem, the professional association of French pharmaceutical companies. Didier was Chairman of the French/European Public Affairs Commission.
Didier is a graduate of Sciences Po Paris and holds a postgraduate degree in Health Law from the University of Paris Sud. Didier is a lecturer at Sciences Po Paris. Didier has been decorated “Chevalier de l’ordre national du Mérite » (National Order of Merit).
